Avalo Therapeutics Inc (AVTX)

2026-08-07T11:45:56.000Z - 7 days ago

Avalo Therapeutics price target lowered to $48 from $50 at Guggenheim

2026-08-07T10:16:11.000Z - 7 days ago

Avalo Therapeutics price target lowered to $30 from $35 at H.C. Wainwright

2026-08-06T11:26:47.000Z - 8 days ago

Avalo Therapeutics reports Q2 EPS (83c), consensus (62c)

Aug 6, 2026, 7:00 AM EDT - 8 days ago

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Aug 6, 2026, 7:00 AM EDT - 8 days ago

Avalo Therapeutics Quarterly report: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 8 days ago

Avalo Therapeutics Earnings release: Q2 2026

Aug 6, 2026, 7:00 AM EDT - 8 days ago

Avalo Therapeutics Slides: Corporate presentation

Jul 22, 2026, 7:00 AM EDT - 23 days ago

Avalo Therapeutics to Participate in the BTIG Biotechnology Conference

2026-07-17T20:05:11.000Z - 4 weeks ago

Avalo Therapeutics files to sell 128,189 shares of common stock for holders

Jul 17, 2026, 8:00 AM EDT - 4 weeks ago

Avalo Therapeutics Registration statement: Registration filing

Jul 7, 2026, 7:00 AM EDT - 5 weeks ago

Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum

2026-07-06T15:10:08.000Z - 5 weeks ago

Avalo Therapeutics initiated with an Outperform at Leerink

2026-06-26T11:15:39.000Z - 7 weeks ago

Avalo Therapeutics to join Russell 2000, Russell 3000

Jun 26, 2026, 7:00 AM EDT - 7 weeks ago

Avalo Therapeutics to Join the Russell 2000® and Russell 3000® Indexes

Jun 23, 2026, 7:00 AM EDT - 7 weeks ago

Avalo Therapeutics Appoints Ron Philip to Board of Directors

2026-06-16T11:06:47.000Z - 2 months ago

Avalo Therapeutics advances AVTX-010

Jun 16, 2026, 7:00 AM EDT - 2 months ago

Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β Antibody

Jun 15, 2026, 7:00 AM EDT - 2 months ago

Avalo Therapeutics Slides: Corporate presentation

2026-06-12T09:51:17.000Z - 2 months ago

Avalo Therapeutics initiated with a Buy at BofA

Jun 2, 2026, 8:30 AM EDT - 2 months ago

Avalo Therapeutics Transcript: AGM 2026

May 22, 2026, 4:01 PM EDT - 3 months ago

Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)

2026-05-14T17:17:08.000Z - 3 months ago

Avalo Therapeutics price target lowered to $34 from $40 at Wedbush

2026-05-14T12:53:14.000Z - 3 months ago

Avalo Therapeutics price target raised to $45 from $39 at Mizuho

2026-05-14T10:17:40.000Z - 3 months ago

Avalo Therapeutics price target lowered to $35 from $40 at H.C. Wainwright

2026-05-14T09:50:09.000Z - 3 months ago

Avalo Therapeutics price target lowered to $55 from $62 at Citizens

2026-05-13T13:05:49.000Z - 3 months ago

Avalo Therapeutics reports Q1 EPS (98c), consensus ($1.01)

May 13, 2026, 7:00 AM EDT - 3 months ago

Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

May 13, 2026, 7:00 AM EDT - 3 months ago

Avalo Therapeutics Earnings release: Q1 2026

May 13, 2026, 7:00 AM EDT - 3 months ago

Avalo Therapeutics Quarterly report: Q1 2026

2026-05-11T13:21:41.000Z - 3 months ago

Avalo Therapeutics price target raised to $60 from $48 at Piper Sandler

2026-05-07T10:13:59.000Z - 3 months ago

Avalo Therapeutics price target raised to $62 from $52 at Citizens

2026-05-07T08:32:34.000Z - 3 months ago

Avalo Therapeutics 19.73M share Spot Secondary priced at $17.75

2026-05-07T07:56:17.000Z - 3 months ago

Avalo Therapeutics price target raised to $58 from $40 at BTIG

2026-05-06T13:03:49.000Z - 3 months ago

Why Is Avalo Therapeutics Stock (AVTX) Up Today?

May 5, 2026, 11:33 PM EDT - 3 months ago

Avalo Therapeutics Announces Pricing of $375 Million Public Offering

May 5, 2026, 4:05 PM EDT - 3 months ago

Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

May 5, 2026, 4:01 PM EDT - 3 months ago

Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa

May 5, 2026, 7:00 AM EDT - 3 months ago

Avalo Therapeutics Slides: Corporate presentation

Apr 28, 2026, 7:00 AM EDT - 3 months ago

Avalo Therapeutics Purchases Optional Milestone Buyout

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Avalo Therapeutics Proxy statement: Proxy filing

Apr 10, 2026, 8:00 AM EDT - 4 months ago

Avalo Therapeutics Proxy statement: Proxy filing

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Avalo Therapeutics Earnings release: Q4 2025

Mar 23, 2026, 7:00 AM EDT - 5 months ago

Avalo Therapeutics Annual report: Q4 2025

Mar 20, 2026, 7:00 AM EDT - 5 months ago

Avalo Therapeutics Slides: Corporate presentation

Mar 10, 2026, 4:20 PM EDT - 5 months ago

Avalo Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 9:50 AM EST - 5 months ago

Avalo Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 10:00 AM EST - 6 months ago

Avalo Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 24, 2026, 7:00 AM EST - 6 months ago

Avalo Therapeutics to Participate in Upcoming Investor Conferences

Feb 18, 2026, 4:05 PM EST - 6 months ago

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Feb 11, 2026, 10:00 AM EST - 6 months ago

Avalo Therapeutics Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Jan 8, 2026, 7:00 AM EST - 7 months ago

Avalo Therapeutics Registration statement: Registration Filing

Dec 2, 2025, 10:30 AM EST - 9 months ago

Avalo Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Nov 30, 2025, 6:00 PM EST - 9 months ago

Avalo Therapeutics Slides: Investor Presentation

Nov 13, 2025, 9:00 AM EST - 9 months ago

Avalo Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 12, 2025, 2:40 PM EST - 9 months ago

Avalo Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 4:00 PM EST - 9 months ago

Avalo Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 6, 2025, 7:00 AM EST - 10 months ago

Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Nov 6, 2025, 7:00 AM EST - 10 months ago

Avalo Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 10 months ago

Avalo Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 6:00 PM EST - 10 months ago

Avalo Therapeutics Slides: Corporate Presentation

Oct 29, 2025, 7:00 AM EDT - 10 months ago

Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Oct 1, 2025, 7:00 AM EDT - 11 months ago

Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources

Sep 22, 2025, 7:00 AM EDT - 11 months ago

Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors

Sep 15, 2025, 11:00 AM EDT - 11 months ago

Avalo Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum

Sep 9, 2025, 2:30 PM EDT - 1 year ago

Avalo Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Avalo Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Avalo Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 7:00 AM EDT - 1 year ago

Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates

Jun 30, 2025, 11:00 AM EDT - 1 year ago

Avalo Therapeutics Transcript: HCW Annual Inflammation & Immunology Virtual Conference 2025

Jun 19, 2025, 2:00 AM EDT - 1 year ago

Avalo Therapeutics Slides: Corporate Presentation

Jun 18, 2025, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

Jun 4, 2025, 7:35 AM EDT - 1 year ago

Avalo Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 12, 2025, 7:00 AM EDT - 1 year ago

Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates

May 12, 2025, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Earnings release: Q1 2025

May 12, 2025, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Quarterly report: Q1 2025

May 8, 2025, 3:00 PM EDT - 1 year ago

Avalo Therapeutics Transcript: The Citizens JMP Life Sciences Conference 2025

May 1, 2025, 8:00 AM EDT - 1 year ago

Avalo Therapeutics Proxy statement: Proxy Filing

May 1, 2025, 8:00 AM EDT - 1 year ago

Avalo Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 7:00 AM EDT - 1 year ago

Avalo Therapeutics to Participate in The Citizens Life Sciences Conference

Mar 26, 2025, 7:00 AM EDT - 1 year ago

Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

Mar 20, 2025, 7:00 AM EDT - 1 year ago

Avalo Reports 2024 Financial Results and Recent Business Updates

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Avalo Therapeutics Earnings release: Q4 2024

Mar 19, 2025, 7:00 PM EDT - 1 year ago

Avalo Therapeutics Annual report: Q4 2024

Mar 3, 2025, 3:10 PM EST - 1 year ago

Avalo Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 11, 2025, 10:00 AM EST - 1 year ago

Avalo Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 4, 2025, 8:00 AM EST - 1 year ago

Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

Jan 11, 2025, 7:00 AM EST - 1 year ago

Avalo Therapeutics Slides: Corporate Presentation

Jan 2, 2025, 7:00 AM EST - 1 year ago

Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer

Nov 12, 2024, 7:00 AM EST - 1 year ago

Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants

Nov 11, 2024, 7:00 AM EST - 1 year ago

Avalo Therapeutics to Present at Upcoming Investor Conferences

Nov 6, 2024, 6:00 PM EST - 1 year ago

Avalo Therapeutics Quarterly report: Q3 2024

Oct 8, 2024, 7:00 AM EDT - 2 years ago

Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa

Sep 9, 2024, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Slides: Corporate Presentation

Aug 11, 2024, 6:00 PM EDT - 2 years ago

Avalo Therapeutics Earnings release: Q2 2024

Aug 11, 2024, 6:00 PM EDT - 2 years ago

Avalo Therapeutics Quarterly report: Q2 2024

Jul 29, 2024, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Registration statement: Registration Filing

Jul 16, 2024, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer

Jul 11, 2024, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Registration statement: Registration Filing

Jul 9, 2024, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1β mAb, to Treat Hidradenitis Suppurativa

Jun 27, 2024, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Jun 27, 2024, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Jun 24, 2024, 4:01 PM EDT - 2 years ago

Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer

Jun 17, 2024, 7:30 AM EDT - 2 years ago

Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit

Jun 7, 2024, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Jun 6, 2024, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Registration statement: Registration Filing

May 13, 2024, 7:30 AM EDT - 2 years ago

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

May 12, 2024, 6:00 PM EDT - 2 years ago

Avalo Therapeutics Earnings release: Q1 2024

May 12, 2024, 6:00 PM EDT - 2 years ago

Avalo Therapeutics Quarterly report: Q1 2024

Apr 2, 2024, 7:00 AM EDT - 2 years ago

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Apr 1, 2024, 6:02 AM EDT - 2 years ago

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Mar 29, 2024, 4:01 PM EDT - 2 years ago

Avalo Reports 2023 Financial Results and Provides Business Updates

Mar 28, 2024, 7:00 PM EDT - 2 years ago

Avalo Therapeutics Annual report: Q4 2023

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Mar 27, 2024, 4:01 PM EDT - 2 years ago

Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

Dec 27, 2023, 7:00 AM EST - 2 years ago

Avalo Therapeutics Announces 1-for-240 Reverse Stock Split

Dec 7, 2023, 7:00 AM EST - 2 years ago

Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split

Dec 7, 2023, 7:00 AM EST - 2 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Nov 9, 2023, 7:00 AM EST - 3 years ago

Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates

Nov 8, 2023, 6:00 PM EST - 3 years ago

Avalo Therapeutics Earnings release: Q3 2023

Nov 8, 2023, 6:00 PM EST - 3 years ago

Avalo Therapeutics Quarterly report: Q3 2023

Oct 31, 2023, 7:00 AM EDT - 3 years ago

Avalo Completes Divestiture of AVTX-800 Series

Oct 19, 2023, 8:00 AM EDT - 3 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Oct 19, 2023, 8:00 AM EDT - 3 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Oct 12, 2023, 11:26 AM EDT - 3 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS MTNB TPST

Oct 5, 2023, 8:00 AM EDT - 3 years ago

Avalo Therapeutics Proxy statement: Proxy Filing

Sep 26, 2023, 7:00 AM EDT - 3 years ago

Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation

Sep 26, 2023, 2:10 AM EDT - 3 years ago

As AVTX stock price soars, Avalo Therapeutics bankruptcy remains

Sep 12, 2023, 7:00 AM EDT - 3 years ago

Avalo Enters into Agreement to Divest AVTX-800 Series

Sep 6, 2023, 7:00 AM EDT - 3 years ago

Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 7:00 AM EDT - 3 years ago

Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates

Aug 2, 2023, 6:00 PM EDT - 3 years ago

Avalo Therapeutics Earnings release: Q2 2023

Aug 2, 2023, 6:00 PM EDT - 3 years ago

Avalo Therapeutics Quarterly report: Q2 2023

Jul 6, 2023, 4:01 PM EDT - 3 years ago

Avalo to Participate in SVB Securities Therapeutics Forum